Annual General Meeting in PhotoCure ASA took place on the 29th of March 2001.
The General Meeting approved the Directors Report and the Annual Accounts as well as the Board of Directors proposed settlement of the deficit for year 2000.
The new Board of Directors of PhotoCure ASA consists of:
Halvor Bjerke, chairman
Per-Olof Mårtensson, deputy chairman
Tharald Brøvig
Erik Engebretsen (new member)
Stener Kvinnsland
Lars Lindegren
Åse Aulie Michelet
Hans Petter Bugge (re-elected as deputy member)
The General Meeting also resolved the items transfer from the share premium account to distributable reserves, authority to the Board to increase the share capital and authority to the Board to acquire own shares in accordance with the proposals of the Board of Directors.
PhotoCure ASA is a Norwegian listed company founded in 1993. PhotoCure ASA's mission is to develop and sell pharmaceuticals and medical devices based on proprietary photodynamic technologies. The company is developing products for skin cancer and other skin diseases, internal cancer, gene therapy and cancer vaccines. Metvix® and Curelight is developed for the treatment of basal cell carcinoma (skin cancer) and actinic keratosis (pre-cancerous skin lesions). PhotoCure's second pharmaceutical product, Hexvix®, is currently undergoing clinical trials for bladder cancer detection. PCI Biotech AS is established as a subsidiary of PhotoCure ASA to develop and commercialise new transfection technologies for the research market as well as products in oncology and gene therapy.
For further information, please contact
PhotoCure ASA
Attn. Vidar Hansson, CEO
Hoffsveien 48
0377 Oslo
Norway
www.photocure.com
E-mail: vh@photocure.no
Telephone: +47 22 06 22 10
Fax: +47 22 06 22 18